MiMedx Group (NASDAQ:MDXG) Reaches New 52-Week Low – Here’s What Happened

MiMedx Group, Inc (NASDAQ:MDXG) reached a new 52-week low during trading on Thursday . The stock traded as low as $4.22 and last traded at $4.2230, with a volume of 295 shares changing hands. The stock had previously closed at $4.24.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MDXG. Mizuho decreased their target price on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Lake Street Capital lowered their price target on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Wall Street Zen downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, UBS Group set a $10.00 target price on shares of MiMedx Group in a research report on Monday, February 23rd. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.60.

MiMedx Group Stock Down 1.1%

The firm has a market cap of $623.25 million, a price-to-earnings ratio of 13.11 and a beta of 1.60. The stock’s 50 day moving average is $5.12 and its 200 day moving average is $6.33. The company has a quick ratio of 3.92, a current ratio of 4.32 and a debt-to-equity ratio of 0.06.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.The company had revenue of $118.10 million for the quarter, compared to the consensus estimate of $106.78 million. Analysts forecast that MiMedx Group, Inc will post 0.3 EPS for the current year.

Institutional Trading of MiMedx Group

Hedge funds and other institutional investors have recently made changes to their positions in the business. World Investment Advisors acquired a new position in MiMedx Group in the fourth quarter worth approximately $173,000. Virtu Financial LLC acquired a new position in shares of MiMedx Group in the 4th quarter worth $78,000. Invesco Ltd. raised its position in shares of MiMedx Group by 5.9% during the fourth quarter. Invesco Ltd. now owns 84,824 shares of the company’s stock worth $574,000 after purchasing an additional 4,708 shares during the period. Corient Private Wealth LLC boosted its position in shares of MiMedx Group by 26.0% in the 4th quarter. Corient Private Wealth LLC now owns 46,658 shares of the company’s stock valued at $316,000 after purchasing an additional 9,614 shares during the period. Finally, Mercer Global Advisors Inc. ADV boosted its position in shares of MiMedx Group by 33.7% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 20,786 shares of the company’s stock valued at $141,000 after purchasing an additional 5,236 shares during the period. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.